Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 2/20 | 0.41 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.41 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.41 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.41 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.41 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.41 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.41 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 6/20 | 0.39 |
| ▸ | GABRP | O00591 | 3/20 | 0.37 |
| ▸ | GABRD | O14764 | 3/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548320 | 0.84 | CYP1A1 (0.36) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL19642363 | 0.84 | CYP1A1 (0.36) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL2516020 | 0.77 | KDM4E (0.57) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL8815403 | 0.77 | ATP1A1 (0.47) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL19642440 | 0.76 | MAOB (0.46) | PRKDCKDM4E | |
| SCHEMBL29547657 | 0.76 | MAOB (0.46) | PRKDCKDM4E | |
| SCHEMBL19642411 | 0.73 | CA12 (0.32) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL29547534 | 0.69 | MAOA (0.64) | MAOAPTGS2EGFRNMUR2KDM4E | |
| SCHEMBL5782106 | 0.69 | MAOA (0.64) | MAOAPTGS2EGFRNMUR2KDM4E | |
| SCHEMBL17265898 | 0.67 | KDM4E (0.32) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3464278-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017202798-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202798-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | XDH, XPOT, HAVCR2 | ATP1A1 1261/4885ATP1B1 949/4885ATP1A3 2287/4885 |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | XDH, HAVCR2, XPA | ATP1A1 1134/4885ATP1B1 835/4885ATP1A3 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.